| name | es-gh-contraindication-tki |
| description | This skill determines if growth hormone treatment should be avoided in childhood cancer survivors with short stature who are currently receiving tyrosine kinase inhibitor therapy (e.g., imatinib, dasatinib). Triggers include: “Should I use GH for short stature in a patient on imatinib?” or “Is GH safe with ongoing TKI therapy?” |
Assess GH contraindication with tyrosine kinase inhibitors
STEP 1 — Gather Information
Confirm childhood cancer survivor status, document current tyrosine kinase inhibitor (TKI) therapy (e.g., imatinib, dasatinib) for malignancy, measure standing height and calculate height SDS, assess for short stature/impaired linear growth (height SDS ≤ -2), and review growth history.
STEP 2 — Rule In / Rule Out
Is the patient currently receiving a tyrosine kinase inhibitor? If yes, proceed to contraindication assessment (Rule In). If no, evaluate for growth hormone deficiency per standard protocols (Rule Out).
STEP 3 — Classify or Stratify
If on TKI, classify as GH contraindicated regardless of GH status; if not on TKI, stratify by GH deficiency status (deficient vs sufficient) using provocative testing.
STEP 4 — Decide
If GH contraindicated (on TKI), do not initiate growth hormone therapy; instead monitor growth, address TKI-related growth suppression with oncology, and consider dose adjustment or temporary hold only under oncologist guidance. If not contraindicated and GH deficient, initiate GH replacement per standard dosing; if GH sufficient, withhold GH and investigate other causes of short stature.
Clinical Guardrails / Mimics / Pitfalls
Do not use GH to overcome TKI-induced growth suppression as efficacy is unproven and may expose patients to unnecessary risk; avoid interpreting low IGF‑I on TKI as GH deficiency without confirmatory testing; never discontinue TKI solely to enable GH without oncologist consultation; monitor for worsened metabolic or skeletal adverse effects if GH is given concomitantly.
Concrete Clinical Example
A 12‑year‑old survivor of Philadelphia‑positive ALL on daily imatinib presents with height ‑2.8 SDS and declining growth velocity; the clinician considers GH for short stature but, per this skill, refrains from GH initiation due to active TKI therapy and instead discusses growth monitoring with the oncologist.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer, Sklar et al., Endocrine Society, 2018, Section 1.4, DOI:10.1210/jc.2018-01175
